Header

UZH-Logo

Maintenance Infos

Double device left atrial appendage closure


Guérios, Enio E; Gloekler, Steffen; Schmid, Michael; Khattab, Ahmed; Nietlispach, Fabian; Meier, Bernhard (2015). Double device left atrial appendage closure. EuroIntervention, 11(4):470-476.

Abstract

Aims: Percutaneous left atrial appendage (LAA) occlusion is an alternative to oral anticoagulation for the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF). Due to the great anatomic variability of the LAA, complete closure may not always be obtained with a single device. We report cases in which adequate closure of the LAA was achieved with implantation of 2 devices. Methods and results: Five out of 223 consecutive patients who underwent LAA occlusion without guidance with transoesophageal echocardiography (TOE) had a second device implanted to treat significant residual leaks or uncovered parts of the LAA after first device implantation. All procedures were successful, with no complications. Two patients received two AMPLATZER Cardiac Plugs (ACP); one patient received one ACP and one AMPLATZER Vascular Plug; one patient received one AMPLATZER Septal Occluder (ASO) and one ACP prototype; and one patient received two ASOs. TOE performed at least four months after the procedure showed complete closure of the LAA in all patients, without thrombus formation on the devices. After 14 patient-years there were no strokes, peripheral thromboemboli, or device embolisations. Conclusions: When necessary, the implantation of two devices to achieve complete LAA occlusion in patients with NVAF is feasible and leads to favourable results during follow-up. Potentially, this technical innovation may widen LAA occlusion indications by permitting occlusion of LAAs with large ostia or complex anatomy.

Abstract

Aims: Percutaneous left atrial appendage (LAA) occlusion is an alternative to oral anticoagulation for the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF). Due to the great anatomic variability of the LAA, complete closure may not always be obtained with a single device. We report cases in which adequate closure of the LAA was achieved with implantation of 2 devices. Methods and results: Five out of 223 consecutive patients who underwent LAA occlusion without guidance with transoesophageal echocardiography (TOE) had a second device implanted to treat significant residual leaks or uncovered parts of the LAA after first device implantation. All procedures were successful, with no complications. Two patients received two AMPLATZER Cardiac Plugs (ACP); one patient received one ACP and one AMPLATZER Vascular Plug; one patient received one AMPLATZER Septal Occluder (ASO) and one ACP prototype; and one patient received two ASOs. TOE performed at least four months after the procedure showed complete closure of the LAA in all patients, without thrombus formation on the devices. After 14 patient-years there were no strokes, peripheral thromboemboli, or device embolisations. Conclusions: When necessary, the implantation of two devices to achieve complete LAA occlusion in patients with NVAF is feasible and leads to favourable results during follow-up. Potentially, this technical innovation may widen LAA occlusion indications by permitting occlusion of LAAs with large ostia or complex anatomy.

Statistics

Citations

1 citation in Web of Science®
2 citations in Scopus®
Google Scholar™

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Cardiology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:22 August 2015
Deposited On:12 Feb 2015 11:38
Last Modified:05 Apr 2016 18:55
Publisher:Europa Edition
ISSN:1774-024X
Publisher DOI:https://doi.org/10.4244/EIJY14M07_03
PubMed ID:25007782

Download

Full text not available from this repository.
View at publisher